Temporal changes in monocyte and macrophage subsets and microglial macrophages following spinal cord injury in the

Sakina G Thawer1, Leah Mawhinney, Kristin Chadwick

  • 1BioTherapeutics Research Laboratories and Spinal Cord Injury Team, Robarts Research Institute, 100 Perth Drive, London, Ontario, Canada, N6A 5K8.

Insights

Hematogenous and microglial macrophages play distinct roles after spinal cord injury (SCI). This study differentiates their responses, revealing specific timing for classical and non-classical macrophage subsets to optimize neuroprotection therapies.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Distinguishing between hematogenous (hMΦ) and microglial (mMΦ) macrophages in spinal cord injury (SCI) lesions is challenging.
  • Previous work established methods to differentiate these macrophage populations using the lys-EGFP-ki mouse model.

Purpose of the Study:

  • To characterize the distinct temporal and spatial responses of monocyte and macrophage subsets, including classical and non-classical hMΦ and mMΦ, following SCI.
  • To elucidate the inflammatory cellular response dynamics in the acute and chronic phases post-SCI.

Main Methods:

  • Utilized the lys-EGFP-ki mouse model to distinguish EGFP(+) hMΦ from EGFP(-) mMΦ.
  • Characterized circulating classical and non-classical monocyte subsets and their presence as hMΦ within the SCI lesion.
  • Analyzed macrophage responses at acute (1d, 3d), sub-acute (7d, 14d), and chronic (6 weeks) time points post-injury.

Main Results:

  • Demonstrated distinct temporal responses: classical pro-inflammatory hMΦ are prominent in acute SCI stages (1-3 days), while non-classical hMΦ dominate the sub-acute phase (7-14 days).
  • Observed the return of classical hMΦ to the injury site at later chronic stages (6 weeks post-injury).
  • First-time characterization of circulating classical and non-classical monocyte subset responses to SCI.

Conclusions:

  • The study provides novel insights into the complex cellular inflammatory response following SCI.
  • Timing and targeting of anti-inflammatory therapies are critical for maximizing neuroprotection in both acute and chronic SCI phases.

Related Concept Videos